Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Altimmune, Inc. stock logo
ALT
Altimmune
$7.26
+0.8%
$9.28
$2.09
$14.84
$514.66M0.055.32 million shs2.25 million shs
magicJack VocalTec Ltd. stock logo
CALL
magicJack VocalTec
$8.67
$0.00
$7.25
$8.70
$140.89M0.69212,501 shsN/A
Cricket Media Group Ltd. stock logo
CKT
Cricket Media Group
C$0.00
C$0.07
C$0.32
N/AN/A607 shsN/A
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
$4.91
+5.8%
$6.45
$3.26
$13.51
$317.43M-0.63853,115 shs495,921 shs
Veris Residential, Inc. stock logo
VRE
Veris Residential
$14.54
-0.8%
$14.81
$13.06
$18.98
$1.34B1.23681,588 shs502,156 shs
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for May 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Altimmune, Inc. stock logo
ALT
Altimmune
+1.69%+4.50%-16.76%-22.83%+37.93%
magicJack VocalTec Ltd. stock logo
CALL
magicJack VocalTec
0.00%0.00%0.00%0.00%0.00%
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
-2.32%+1.09%-24.68%-13.27%-63.44%
Veris Residential, Inc. stock logo
VRE
Veris Residential
-2.72%+3.39%+0.69%-7.40%-5.54%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Altimmune, Inc. stock logo
ALT
Altimmune
1.358 of 5 stars
3.31.00.00.03.11.70.0
magicJack VocalTec Ltd. stock logo
CALL
magicJack VocalTec
N/AN/AN/AN/AN/AN/AN/AN/A
Cricket Media Group Ltd. stock logo
CKT
Cricket Media Group
N/AN/AN/AN/AN/AN/AN/AN/A
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
4.1144 of 5 stars
3.42.00.04.13.33.30.0
Veris Residential, Inc. stock logo
VRE
Veris Residential
1.3294 of 5 stars
2.31.01.70.01.12.51.3

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Altimmune, Inc. stock logo
ALT
Altimmune
2.67
Moderate Buy$15.00106.61% Upside
magicJack VocalTec Ltd. stock logo
CALL
magicJack VocalTec
N/AN/AN/AN/A
Cricket Media Group Ltd. stock logo
CKT
Cricket Media Group
N/AN/AN/AN/A
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
2.75
Moderate Buy$14.94204.23% Upside
Veris Residential, Inc. stock logo
VRE
Veris Residential
2.67
Moderate Buy$17.0016.92% Upside

Current Analyst Ratings

Latest CALL, ALT, CKT, VRE, and TERN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/9/2024
Veris Residential, Inc. stock logo
VRE
Veris Residential
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetHold ➝ Hold$15.00 ➝ $14.00
4/1/2024
Altimmune, Inc. stock logo
ALT
Altimmune
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$15.00 ➝ $12.00
3/28/2024
Altimmune, Inc. stock logo
ALT
Altimmune
B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$20.00
3/27/2024
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$19.00 ➝ $18.00
3/18/2024
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$17.00 ➝ $15.00
3/15/2024
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$5.50
3/15/2024
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$18.00 ➝ $19.00
2/13/2024
Altimmune, Inc. stock logo
ALT
Altimmune
B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$20.00
(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Altimmune, Inc. stock logo
ALT
Altimmune
$430K1,196.89N/AN/A$2.75 per share2.64
magicJack VocalTec Ltd. stock logo
CALL
magicJack VocalTec
$87.99M1.60$3.15 per share2.75$3.03 per share2.86
Cricket Media Group Ltd. stock logo
CKT
Cricket Media Group
N/AN/AN/AN/AN/AN/A
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
$1M317.43N/AN/A$4.13 per share1.19
Veris Residential, Inc. stock logo
VRE
Veris Residential
$279.86M4.79N/AN/A$13.88 per share1.05

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Altimmune, Inc. stock logo
ALT
Altimmune
-$88.45M-$1.65N/AN/AN/A-20,780.75%-44.77%-40.72%5/9/2024 (Estimated)
magicJack VocalTec Ltd. stock logo
CALL
magicJack VocalTec
-$24.96MN/A8.18N/A8.09%39.19%11.85%N/A
Cricket Media Group Ltd. stock logo
CKT
Cricket Media Group
N/AN/A0.00N/AN/AN/AN/AN/AN/A
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
-$90.21M-$1.27N/AN/AN/AN/A-33.55%-31.90%5/20/2024 (Estimated)
Veris Residential, Inc. stock logo
VRE
Veris Residential
-$107.26M-$1.00N/A25.512.90-32.51%-10.35%-3.92%7/24/2024 (Estimated)

Latest CALL, ALT, CKT, VRE, and TERN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
3/27/2024Q4 2023
Altimmune, Inc. stock logo
ALT
Altimmune
-$0.35-$0.33+$0.02-$0.12N/A$0.04 million
3/14/2024Q4 2023
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
-$0.29-$0.29N/A-$0.29N/AN/A

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Altimmune, Inc. stock logo
ALT
Altimmune
N/AN/AN/AN/AN/A
magicJack VocalTec Ltd. stock logo
CALL
magicJack VocalTec
N/AN/AN/AN/AN/A
Cricket Media Group Ltd. stock logo
CKT
Cricket Media Group
N/AN/AN/AN/AN/A
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
N/AN/AN/AN/AN/A
Veris Residential, Inc. stock logo
VRE
Veris Residential
$0.211.44%-44.51%N/A N/A

Latest CALL, ALT, CKT, VRE, and TERN Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
2/29/2024
Veris Residential, Inc. stock logo
VRE
Veris Residential
Quarterly$0.05201.4%4/2/20244/3/20244/16/2024
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Altimmune, Inc. stock logo
ALT
Altimmune
N/A
17.26
17.26
magicJack VocalTec Ltd. stock logo
CALL
magicJack VocalTec
N/A
1.51
1.38
Cricket Media Group Ltd. stock logo
CKT
Cricket Media Group
N/AN/AN/A
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
N/A
22.39
22.39
Veris Residential, Inc. stock logo
VRE
Veris Residential
1.45
1.01
1.01

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Altimmune, Inc. stock logo
ALT
Altimmune
78.05%
magicJack VocalTec Ltd. stock logo
CALL
magicJack VocalTec
66.14%
Cricket Media Group Ltd. stock logo
CKT
Cricket Media Group
N/A
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
98.26%
Veris Residential, Inc. stock logo
VRE
Veris Residential
93.04%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Altimmune, Inc. stock logo
ALT
Altimmune
5970.89 million67.99 millionOptionable
magicJack VocalTec Ltd. stock logo
CALL
magicJack VocalTec
N/A16.25 millionN/AOptionable
Cricket Media Group Ltd. stock logo
CKT
Cricket Media Group
147,000N/AN/ANot Optionable
Terns Pharmaceuticals, Inc. stock logo
TERN
Terns Pharmaceuticals
6664.65 million53.40 millionNot Optionable
Veris Residential, Inc. stock logo
VRE
Veris Residential
19792.23 million78.40 millionOptionable

CALL, ALT, CKT, VRE, and TERN Headlines

SourceHeadline
Veris Residential Inc (VRE) (Q1 2024) Earnings Call Transcript Highlights: Navigating Growth ...Veris Residential Inc (VRE) (Q1 2024) Earnings Call Transcript Highlights: Navigating Growth ...
finance.yahoo.com - April 26 at 7:59 AM
Veris Residential, Inc. 2024 Q1 - Results - Earnings Call PresentationVeris Residential, Inc. 2024 Q1 - Results - Earnings Call Presentation
seekingalpha.com - April 25 at 7:22 AM
Veris Residential Inc (VRE) Q1 2024 Earnings: A Detailed OverviewVeris Residential Inc (VRE) Q1 2024 Earnings: A Detailed Overview
finance.yahoo.com - April 24 at 10:22 PM
VRE Stock Earnings: Veris Residential Beats EPS, Misses Revenue for Q1 2024VRE Stock Earnings: Veris Residential Beats EPS, Misses Revenue for Q1 2024
msn.com - April 24 at 10:22 PM
Veris (VRE) Reports Q1 Earnings: What Key Metrics Have to SayVeris (VRE) Reports Q1 Earnings: What Key Metrics Have to Say
zacks.com - April 24 at 8:36 PM
Veris Residential (NYSE:VRE) Issues FY 2024 Earnings GuidanceVeris Residential (NYSE:VRE) Issues FY 2024 Earnings Guidance
marketbeat.com - April 24 at 6:13 PM
Veris Residential reports Q1 resultsVeris Residential reports Q1 results
msn.com - April 24 at 5:22 PM
Veris Residential, Inc. Reports First Quarter 2024 ResultsVeris Residential, Inc. Reports First Quarter 2024 Results
prnewswire.com - April 24 at 4:20 PM
Nasdaq Futures Climb on Tesla Boost, Meta Earnings in FocusNasdaq Futures Climb on Tesla Boost, Meta Earnings in Focus
msn.com - April 24 at 7:21 AM
OVERSEA CHINESE BANKING Corp Ltd Purchases 147,807 Shares of Veris Residential, Inc. (NYSE:VRE)OVERSEA CHINESE BANKING Corp Ltd Purchases 147,807 Shares of Veris Residential, Inc. (NYSE:VRE)
marketbeat.com - April 20 at 4:23 PM
Veris Residential (VRE) Scheduled to Post Earnings on WednesdayVeris Residential (VRE) Scheduled to Post Earnings on Wednesday
americanbankingnews.com - April 17 at 3:10 AM
Veris Residential, Inc. Announces Dates for First Quarter 2024 Financial Results and WebcastVeris Residential, Inc. Announces Dates for First Quarter 2024 Financial Results and Webcast
finance.yahoo.com - April 15 at 10:21 AM
Veris Residential, Inc. (NYSE:VRE) Short Interest Down 27.4% in MarchVeris Residential, Inc. (NYSE:VRE) Short Interest Down 27.4% in March
marketbeat.com - April 12 at 2:50 PM
Truist Financial Lowers Veris Residential (NYSE:VRE) Price Target to $14.00Truist Financial Lowers Veris Residential (NYSE:VRE) Price Target to $14.00
marketbeat.com - April 9 at 2:26 PM
Veris Residential (NYSE:VRE) Trading 5.8% Higher Veris Residential (NYSE:VRE) Trading 5.8% Higher
marketbeat.com - April 8 at 1:45 PM
Veris Residential Declares Quarterly Cash DividendVeris Residential Declares Quarterly Cash Dividend
prnewswire.com - February 29 at 5:26 PM
Veris Residential beats top-line and bottom-line estimates; initiates FY24 outlookVeris Residential beats top-line and bottom-line estimates; initiates FY24 outlook
msn.com - February 22 at 10:44 AM
Veris Residential, Inc. 2023 Q4 - Results - Earnings Call PresentationVeris Residential, Inc. 2023 Q4 - Results - Earnings Call Presentation
seekingalpha.com - February 22 at 8:50 AM
Veris Residential (VRE) Surpasses Q4 FFO and Revenue EstimatesVeris Residential (VRE) Surpasses Q4 FFO and Revenue Estimates
finance.yahoo.com - February 21 at 11:28 PM
Veris Residential, Inc. Reports Fourth Quarter and Full Year 2023 ResultsVeris Residential, Inc. Reports Fourth Quarter and Full Year 2023 Results
finance.yahoo.com - February 21 at 11:28 PM
Compared to Estimates, Veris (VRE) Q4 Earnings: A Look at Key MetricsCompared to Estimates, Veris (VRE) Q4 Earnings: A Look at Key Metrics
zacks.com - February 21 at 9:30 PM
Veris Residential (VRE) Surpasses Q4 FFO and Revenue EstimatesVeris Residential (VRE) Surpasses Q4 FFO and Revenue Estimates
zacks.com - February 21 at 8:41 PM
Veris Residential, Inc. Reports Fourth Quarter and Full Year 2023 ResultsVeris Residential, Inc. Reports Fourth Quarter and Full Year 2023 Results
prnewswire.com - February 21 at 7:04 PM
Veris Residential Inc (VRE) Reports Solid Growth in Core FFO and NOI for FY 2023Veris Residential Inc (VRE) Reports Solid Growth in Core FFO and NOI for FY 2023
finance.yahoo.com - February 21 at 6:28 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

Altimmune logo

Altimmune

NASDAQ:ALT
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.
magicJack VocalTec logo

magicJack VocalTec

NASDAQ:CALL
magicJack VocalTec Ltd., together with its subsidiaries, operates as a cloud communications company in the United States. The company's products and services allow users to make and/or receive free telephone calls to and from where the customer has broadband access to the Internet. It provides magicJack devices, such as The magicJack, magicJack PLUS, New magicJack PLUS, magicJack GO, and magicJack EXPRESS, which are voice-over-Internet-Protocol (VoIP) devices that enables customers to receive free VoIP phone service for their home, enterprise, or while traveling. The company also offers magicJack APP, an application that allows users to make and receive telephone calls through their smart phones using their magicJack account, as well as access to servers for a fee on a monthly or annual basis; and magicJack Connect App that offers Wi-Fi app-to-app calling and messaging services, as well as unlimited calling plans for the United States subscribers. In addition, it provides other magicJack-related products; and wholesales telephone services to VoIP providers and telecommunication carriers. Further, the company offers hosted unified communication as a service, as well as sells related hardware and network equipment to blue chip corporate customers; and VoIP services to small to medium sized businesses. It distributes its products through retail outlets, as well as direct sales. magicJack VocalTec Ltd. was founded in 1989 and is headquartered in Netanya, Israel.
Cricket Media Group logo

Cricket Media Group

CVE:CKT
Cricket Media Group Ltd. (Cricket Media) is a United States-based education media company. The Company provides content on a learning network for children, families and teachers across the world. Its media brands for toddlers to teens include Babybug, Ladybug, Cricket and Cobblestone. The Company's products include magazines under categories, such as Ask, Cicada, Babybug, Click, Cricket, Cobblestone, Dig, Faces, Ladybug, Muse and Spider; educational toys; books; teacher guides; content library, and Story Bug application. Its Web-based K12 tools for school and home include the ePals community and virtual classroom for global collaboration, as well as In2Books, a Common Core eMentoring program that builds reading, writing and critical thinking skills. It serves teachers, students and parents in over 200 countries and territories through its platform and NeuPals, its joint venture with China-based information technology services company Neusoft.
Terns Pharmaceuticals logo

Terns Pharmaceuticals

NASDAQ:TERN
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of MASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.
Veris Residential logo

Veris Residential

NYSE:VRE
Veris Residential, Inc. is a forward-thinking, environmentally and socially conscious real estate investment trust (REIT) that primarily owns, operates, acquires and develops holistically-inspired, Class A multifamily properties that meet the sustainability-conscious lifestyle needs of today's residents while seeking to positively impact the communities it serves and the planet at large. The company is guided by an experienced management team and Board of Directors and is underpinned by leading corporate governance principle; a best-in-class and sustainable approach to operations; and an inclusive culture based on equality and meritocratic empowerment.